We partner with a secure submission system to handle manuscript submissions.
Please note:
You will need an account for the submission system, which is separate to your Cambridge Core account. For login and submission support, please visit the
submission and support pages.
Please review this journal's author instructions, particularly the
preparing your materials
page, before submitting your manuscript.
Click Proceed to submission system to continue to our partner's website.
To save this undefined to your undefined account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you used this feature, you will be asked to authorise Cambridge Core to connect with your undefined account.
Find out more about saving content to .
To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
Epilepsy is a relatively common condition that affects approximately 4–5 per 1000 individuals in Ontario, Canada. While genetic testing is now prevalent in diagnostic and therapeutic care plans, optimal test selection and interpretation of results in a patient-specific context can be inconsistent and provider dependent.
Methods:
The first of its kind, the Ontario Epilepsy Genetic Testing Program (OEGTP) was launched in 2020 to develop clinical testing criteria, curate gene content, standardize the technical testing criteria through a centralized testing laboratory, assess diagnostic yield and clinical utility and increase genetics literacy among providers.
Results:
Here we present the results of the first two years of the program, demonstrating the overall 20.8% diagnostic yield including pathogenic sequence and copy number variation detected by next-generation sequencing panels. Routine follow-up testing of family members enabled the resolution of ambiguous findings. Post-test outcomes were collected as reported by the ordering clinicians, highlighting the clinical benefits of genetic testing.
Conclusion:
This programmatic approach to genetic testing in epilepsy by OEGTP, together with engagement of clinical and laboratory stakeholders, provided a unique opportunity to gather insight into province-wide implementation of a genetic testing program.
Retinal artery occlusion (RAO) is a vision-threatening condition with limited therapeutic options. Hyperbaric oxygen therapy (HBOT) has emerged as a potential treatment to enhance retinal oxygenation and salvage ischemic tissue, though its efficacy and safety remain debated.
Methods:
We followed the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines and the Cochrane Handbook for Systematic Reviews of Interventions. Databases were searched through November 2024 for studies comparing HBOT with control in RAO patients. Risk of bias was assessed using the Newcastle-Ottawa Scale. Meta-analyses evaluated visual acuity (VA), best-corrected visual acuity (BCVA) and adverse events (AEs).
Results:
Nine studies with 499 patients (286 HBOT, 213 non-HBOT) met the inclusion criteria. HBOT was associated with improved BCVA (MD: –0.63, 95% CI: [–1.14, –0.12], p = 0.01) after sensitivity analysis. No significant differences were observed in uncorrected VA or lines of improvement. AEs included seizures (1.47%), ear barotrauma (1.65%) and epistaxis (0.83%) in the HBOT group. Notably, HBOT was associated with lower rates of neovascular glaucoma (7.89% vs. 15.79%) and stroke (4.3% vs. 16.6%) compared to controls.
Conclusions:
HBOT demonstrates potential for improved visual outcomes in RAO patients, particularly BCVA, with a generally favorable safety profile. However, heterogeneity among studies and limited sample sizes highlight the need for robust prospective trials to clarify its role in RAO management.
Up-to-date certification of the National Institutes of Health Stroke Scale (NIHSS) and modified Rankin Scale (mRS) is often required for clinical trials, representing a significant burden on clinical investigators globally.
Aims:
This systematic review sought to determine if NIHSS or mRS training, re-training, certification or recertification led to improvements in the reliability or accuracy of ratings as well as other relevant user metrics (e.g., user confidence).
Results:
Among 4227 studies, 100 passed screening and were assessed for eligibility with full-text review; 23 met inclusion criteria. Among these 23 studies, 22 examined NIHSS training and/or certification, and only a single study included examined the effect of training on mRS performance. Ten of 23 included studies were conference abstracts. The study designs, interventions and outcome measurement of the included studies were heterogeneous. In the case of the NIHSS, two studies found increased accuracy after NIHSS training, and a third study showed statistically significant though clinically trivial decreases in error rate with training. The remaining 19 studies showed no benefit of NIHSS training as it relates to reliability or accuracy outcomes. The single included mRS study did not show the benefit of training.
Conclusion:
Although data are sparse with heterogeneous training protocols and outcomes, there is no compelling evidence to suggest benefit of healthcare professionals completing NIHSS or mRS training, certification or recertification. At the very least, recertification/re-training requirements should be reconsidered pending the provision of robust evidence.
Stroke due to basilar artery occlusion (BAO) carries poor outcomes despite advancements in endovascular therapy (EVT). Predictors of recovery remain underexplored. This study evaluates clinical and imaging predictors of outcomes following EVT, including a Critical Area Diffusion Score (CADS), assessing infarct location and extent in critical brainstem regions on post-EVT MRI.
Methods:
This retrospective study analyzed 48 BAO patients treated with EVT at a provincial stroke center (2015–2021). Patients were categorized by outcomes (favorable: modified Rankin Scale [mRS] 0–3; unfavorable: mRS 4–6). Clinical, demographic and imaging data – age, baseline National Institutes of Health Stroke Scale (NIHSS), reperfusion success (thrombolysis in cerebral infarction [TICI] 2b–3) and post-EVT CADS from diffusion-weighted MRI – were assessed using univariate and multivariate logistic regression.
Results:
Patients with favorable outcomes were younger (median 64.0 vs. 73.0 years, p = 0.031), had lower NIHSS scores at presentation (median 8 vs. 16, p = 0.018) and achieved higher successful reperfusion rates (81.0% vs. 48.1%, p = 0.020). CADS ≤ 3 was linked to better outcomes (median mRS 3 vs. 5, p = 0.026) and higher odds of recovery in univariate analysis (OR = 10.89, p = 0.038). However, in multivariate analysis, CADS was not an independent predictor, with successful reperfusion (OR = 18.8, p = 0.044) as the strongest factor.
Conclusion:
Age, NIHSS scores and successful reperfusion predict recovery in BAO patients undergoing EVT. Although CADS ≤ 3 is linked to favorable outcomes, it is not independently predictive. CADS holds promise as a prognostic tool, but its utility should be considered alongside clinical markers to enhance outcome prediction in BAO.
Cortical excitability has been proposed as a novel neurophysiological marker of neurodegeneration in Alzheimer’s dementia (AD). However, the link between cortical excitability and structural changes in AD is not well understood.
Objective:
To assess the relationship between cortical excitability and motor cortex thickness in AD.
Methods:
In 62 participants with AD (38 females, mean ± SD age = 74.6 ± 8.0) and 47 healthy control (HC) individuals (26 females, mean ± SD age = 71.0 ± 7.9), transcranial magnetic stimulation resting motor threshold (rMT) was determined, and T1-weighted MRI scans were obtained. Skull-to-cortex distance was obtained manually for each participant using MNI coordinates of the motor cortex (x = −40, y = −20, z = 52).
Results:
The mean skull-to-cortex distances did not differ significantly between participants with AD (22.9 ± 4.3 mm) and HC (21.7 ± 4.3 mm). Participants with AD had lower motor cortex thickness than healthy individuals (t(92) = −4.4, p = <0.001) and lower rMT (i.e., higher excitability) than HC (t(107) = −2.0, p = 0.045). In the combined sample, rMT was correlated positively with motor cortex thickness (r = 0.2, df = 92, p = 0.036); however, this association did not remain significant after controlling for age, sex and diagnosis.
Conclusions:
Patients with AD have decreased cortical thickness in the motor cortex and higher motor cortex excitability. This suggests that cortical excitability may be a marker of neurodegeneration in AD.
The best prehospital transport strategy for patients with suspected stroke due to possible large vessel occlusion varies by jurisdiction and available resources. A foundational problem is the lack of a definitive diagnosis at the scene. Rural stroke presentations provide the most problematic triage destination decision-making. In Alberta, Canada, the implementation and 5-year experience with a rural field consultation approach to provide service to rural patients with acute stroke is described.
Methods:
The protocols established through the rural field consultation system and the subsequent transport patterns for suspected stroke patients during the first 5 years of implementation are presented. Outcomes are reported using home time and data are summarized using descriptive statistics.
Results:
From April 2017 to March 2022, 721 patients met the definition for a rural field consultation, and 601 patients were included in the analysis. Most patients (n = 541, 90%) were transported by ground ambulance. Intravenous thrombolysis was provided for 65 (10.8%) of patients, and 106 (17.6%) underwent endovascular thrombectomy. The median time from first medical contact to arterial access was 3.2 h (range 1.3–7.6) in the direct transfers, compared to 6.5 h (range 4.6–7.9) in patients arriving indirectly to the comprehensive stroke center (CSC). Only a small proportion of patients (n = 5, 0.8%) were routed suboptimally to a primary stroke center and then to a CSC where they underwent endovascular therapy.
Conclusions:
The rural field consultation system was associated with shortened delays to recanalization and demonstrated that it is feasible to improve access to acute stroke care for rural patients.
The literature on cortical excitability, inhibitory and facilitatory properties of the brain in patients with primary dystonia is not well elucidated. We aimed to study the changes in these neurophysiological parameters in patients with dystonia using transcranial magnetic stimulation (TMS).
Methods:
Patients with primary dystonia of presumed genetic etiology (n = 36) and an equal number of healthy controls (HC) (n = 36) were recruited from May 2021 to September 2022. TMS was done using single and paired pulse paradigms. The left motor cortex was stimulated, and responses were recorded from the contralateral first dorsal interosseus muscle. Resting motor threshold (RMT), central motor conduction time, contralateral silent period (cSP), ipsilateral silent period (iSP), short-interval intracortical inhibition (SICI) and intracortical facilitation (ICF) were recorded. All patients underwent whole exome sequencing.
Results:
The mean age of patients was 36.6 ± 13.5 years. There was a significant reduction of cSP (79.5 ± 33.8 vs 97.5 ± 25.4, p = 0.02) and iSP (42.3 ± 13.5 vs 53.8 ± 20.8, p = 0.003) in patients compared to HC. SICI was significantly enhanced in patients (0.38 ± 0.23) compared to HC (0.51 ± 0.24, p = 0.006). RMT was higher (42.1 ± 7.9 vs 37.1 ± 6.4%, p = 0.032) with enhanced SICI (0.36 ± 0.21 vs 0.56 ± 0.25, p = 0.004) in patients with generalized dystonia (n = 20) compared to HC. The genetically determined subgroup (n = 13) had significantly enhanced SICI compared to HC (0.23 ± 0.15 vs 0.51 ± 0.23, p = 0.001).
Conclusions:
Patients with primary dystonia have altered cortical excitability and inhibition with significantly reduced silent period and enhanced intracortical inhibition suggestive of impaired GABAergic neurotransmission.
Canada’s National Microbiology Laboratory offers diagnostic testing of Creutzfeldt-Jakob disease (CJD) and related prion diseases. Since 2016, the highly sensitive and specific end-point quaking-induced conversion assay (EP-QuIC) of CSF samples has been used for antemortem CJD diagnostic testing alongside tests for surrogate biomarkers 14-3-3 and hTau. To assess EP-QuIC’s utility, we undertook a retrospective study of Canadian CJD diagnostic testing conducted between 2016 and 2024.
Methods:
Using CJD CSF test results collected between 2016 and 2024, we analyzed the CJD incidence in Canada, estimated based on positive EP-QuIC tests. Multivariate regression models were used to further evaluate CJD CSF testing between CJD subtypes, genders, age groups and codon 129 genotypes.
Results:
From 2016 to 2024, the CJD incidence across Canada was estimated at 1.51 cases per million population per year. CJD incidence did not vary significantly across provinces, although a slight increase in CJD incidence was detected in New Brunswick due to increased sampling rates. EP-QuIC offered higher test sensitivity than both surrogate biomarker tests. Analysis of biomarker abundances and test positivity rates across biochemical subtypes revealed significant differences. We also detected variation in CSF test positivity rates across age groups and a trend of increasing biomarker abundance with age within EP-QuIC-negative cases. No significant variation was detected between males and females.
Conclusion:
EP-QuIC exhibits exceptional specificity and sensitivity for antemortem diagnosis of CJD, providing a valuable tool for the diagnosis of human prion diseases and for improved surveillance.
The aim of this study is to assess the evolution of respiratory and feeding support in children with spinal muscular atrophy (SMA) type 1 after 24 months of nusinersen treatment.
Methods:
Data on SMA type 1 children treated with nusinersen between 2017 and 2023 from the Canadian Neuromuscular Disease Registry were extracted. The cohort was divided into two groups based on age at treatment initiation: ≤2 years and >2 years. The primary outcome was the (i) time to death or needing full-time (≥16 hours/day) ventilation and (ii) time to needing feeding tube support. The secondary outcomes were differences in respiratory and feeding support requirements between the two groups at 24-month follow-up.
Results:
Thirty-two children were included, and the median age (range) for treatment initiation was 3.2 months (0.8– 13.1) in children who initiated treatment at ≤2 years and 51.2 (28.7–183.8) in those who initiated at >2 years of age. The median age of death or full-time ventilation was 8.6 months (6–22.4) and 10.5 months (4–24) for the two groups, respectively. The median age for initiation of feeding support was 5.1 (1.7–26.4) and 14.5 months (3.9–130.6), respectively. At 24 months (n = 23), there were no significant differences between the need for respiratory or feeding tube support between the two treatment groups.
Conclusion:
Most children with SMA type 1 treated with nusinersen across Canada have continued need for respiratory and feeding support over time when initiated after symptom onset.
Early diagnosis of neurodegenerative diseases (NDs) is a priority with the advent of disease-modifying therapies. The study of prodromal non-motor symptoms (NMS) in ND could help guide early diagnosis, facilitating adequate treatment. The primary objective of this study was to determine the prodromal association between NMS and ND.
Methods:
A retrospective cohort study was planned. Records of subjects attending the movement disorders and NDs unit from Hospital Civil de Guadalajara “Fray Antonio Alcalde,” from 2012 to January 2025, were evaluated. Subjects with NMSQuest questionnaire in ND were included. Descriptive and inferential parametric statistics (Student’s t-test for independent samples and ANOVA) were used, and odds ratios (OD) with 95% confidence interval were calculated using binary logistic regression. A p value < 0.05 was considered significant.
Results:
The most frequent prodromal NMS in ND were depression, constipation, insomnia, anxiety and pain. There was an average of 7.7 ± 7.6 years of prodromal NMS prior to the diagnosis of ND. Prodromal depression [OR 1.9 (1.1–3.5 p < 0.001) and confusion/delusional thoughts [OR 7.2 (1.3–39.2) p = 0.02] were associated with dementia (time onset prior to diagnosis 9.9 ± 12.2 and 5.5 ± 9.7 years, respectively). Prodromal restless legs syndrome was associated with movement disorders [OR 3.3 (1.1–9.7) p = 0.02] (time onset 4.7 ± 6.9 years prior to diagnosis).
Conclusion:
Evidence points to a potential association of prodromal NMS in ND. Prospective studies are required to confirm and characterize the association between prodromal NMS and ND, as their early identification may contribute to the timely diagnosis of ND.
Adult-onset PLA2G6-associated neurodegeneration (PLAN) has a diverse phenotypic presentation.
Objective:
Detailed description of the clinical, imaging and genetic profile of adult-onset PLAN; comparison of the Indian cohort with Asian, Middle East and European cohorts; genotype–phenotype correlations; and determination of ethnic phenotypic and genotypic differences of adult-onset PLAN.
Methods:
Report of two patients of adult-onset PLAN and review of reported cases of adult-onset PLAN since 2015 from Indian, Asian, Middle East and European cohorts.
Results:
There were 12 cases in the Indian cohort, 45 in the Asian cohort, 10 in the Middle East cohort and 17 in European cohort. Patients in the Indian and Asian cohorts had a later age at onset as compared to the Middle East and European cohorts. The median duration of disease was similar among all cohorts. Dystonia, myoclonus and gaze palsy were common in the Indian cohort; parkinsonism and tremor in the Asian cohort; parkinsonism, tremor, spasticity and cognitive impairment in the Middle East cohort; and parkinsonism and behavioural disturbances in the European cohort. Early-onset parkinsonism was common in all cohorts. Mineralisation on MRI was less frequent in the Asian and Middle East cohorts. Cerebral/cerebellar atrophy was less frequent in the Asian cohort. The homozygous missense variant (c.2222G > A,p.R741Q) was common in the Indian and Middle East cohorts, whereas the homozygous/compound heterozygous variant (c.991G > T, p.D331Y) was the most common variant in the Asian cohort. Milder clinical and neuroimaging phenotypes were noted with c.991G > T (p.D331Y) variant and a relatively severe phenotype in c.2222G > A,p.R741Q variant.
Conclusion:
Adult-onset PLAN has a variable phenotype. We found ethnic phenotypic and imaging differences among the cohorts.
Noninvasive stimulation techniques are a promising therapy due to the ease of administration and minimal side effects. We investigated the clinical, electrophysiological and side effects of transcranial pulsed current stimulation (tPCS) in patients with Parkinson’s disease (PD).
Materials and Methods:
Ten PD patients were called at monthly intervals in the OFF levodopa state. Patients received active tPCS for 20 minutes in the first visit and sham stimulation for 20 minutes in the second and were assessed for the levodopa response in the third. Clinical and bradykinesia scoring and gait and tremor analysis were done before and after stimulation/sham/levodopa in each visit. Scalp electroencephalography (EEG) was recorded for quantitative analysis during each visit. The interventions were compared between pre- and post-intervention.
Results:
A significant improvement with levodopa as compared to active and sham tPCS was seen in clinical scores. Upper limb postural tremor severity (z-score = −2.410, p = 0.016) and the stride velocity variability during post active stimulation improved by 20.7% compared to post sham stimulation though the difference was statistically non-significant. KINARM testing showed a statistically significant difference in the reaction time (p = 0.036) when comparing pre- and post-tPCS active stimulation. EEG recording showed a transitory increase of electrical activity after tPCS, with the most significant increase seen in alpha bandpower (p = 7.95*10-07; z score: −4.93).
Conclusions:
tPCS was well tolerated in all patients. With minimal side effects, ease of administration and mild improvement in the electrophysiological parameters assessed, tPCS can be an alternative therapeutic option in patients with PD.
Historically, it has been proposed that functional neurological symptoms occur more frequently on the left side of the body due to a distinct body representation and emotional processing of the right hemisphere, yet objective imaging data to support this are lacking. We aimed to investigate whether patients with acute left-sided symptoms (right hemisphere) suspected of having a minor stroke are more likely to show negative diffusion-weighted imaging (DWI) compared to those with right-sided symptoms.
Methods:
Data are from the SpecTRA (Spectrometry for Transient Ischemic Attack Rapid Assessment) multicenter prospective cohort study conducted between 2013 and 2017. Patients with mild persistent unilateral hemiparesis and/or hemisensory symptoms (National Institute of Health Stroke Scale ≤ 3) and available DWI were included. The primary outcome was the proportion of patients with a negative DWI.
Results:
Of 1731 patients, 584 (30.8%) were included. Of these, 310 (53.1%) patients presented with left-sided symptoms and 274 (46.9%) with right-sided symptoms. Overall, 214 (36.6%) patients had a negative DWI, 126 (58.9%) with left-sided symptoms and 88 (41.1%) with right-sided symptoms: risk ratio (RR) 1.27 (95% CI = 1.02–1.57). Left-sided hemiparesis was associated with negative DWI (RR 1.42 [95% CI = 1.08–1.87]), while left-sided hemisensory symptoms were not (RR 1.11 [95% CI = 0.87–1.41]). There was no effect modification by age or sex on this association (Pinteraction 0.787 and 0.057, respectively).
Conclusions:
Unilateral left-sided neurological symptoms were more frequently associated with negative DWI compared to right-sided symptoms in suspected minor stroke patients. This observation is exploratory, as the final diagnosis in DWI-negative cases was not established.